Targeted therapies for certain types of cancer and rare disease offer new hope for these patient populations. But how can we ensure that these treatments are also developed with minority communities in mind?
Moderator: Kemi Olugemo, MD, Executive Medical Director, Neurology Clinical Development, Ionis Pharmaceuticals, Inc.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Speakers:
Kate Burke, MD, Senior Medical Advisor, PatientsLikeMe
Elisabeth Heath, MD, Associate Center Director, Translational Sciences Chair, Genitourinary Oncology Multidisciplinary Team, Karmanos Cancer Institute
Alyshia Merchant, Founder, Making Lupus Look Good